Literature DB >> 20606142

FDA: Benefits of rotavirus vaccination outweigh potential contamination risk.

Bridget M Kuehn.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20606142     DOI： 10.1001/jama.2010.863

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome.

Authors:  Gary Dubin; Jean-François Toussaint; Jean-Pol Cassart; Barbara Howe; Donna Boyce; Leonard Friedland; Remon Abu-Elyazeed; Sylviane Poncelet; Htay Htay Han; Serge Debrus
Journal:  Hum Vaccin Immunother       Date:  2013-08-28       Impact factor: 3.452

2.  Detection of PCV-2 DNA in stool samples from infants vaccinated with RotaTeq®.

Authors:  Mathew D Esona; Slavica Mijatovic-Rustempasic; Catherine Yen; Umesh D Parashar; Jon R Gentsch; Michael D Bowen; Philip LaRussa
Journal:  Hum Vaccin Immunother       Date:  2013-10-08       Impact factor: 3.452

3.  A multi-center, qualitative assessment of pediatrician and maternal perspectives on rotavirus vaccines and the detection of Porcine circovirus.

Authors:  Daniel C Payne; Sharon Humiston; Douglas Opel; Allison Kennedy; Mary Wikswo; Kimberly Downing; Eileen J Klein; Ana Kobayashi; David Locke; Christina Albertin; Claudia Chesley; Mary A Staat
Journal:  BMC Pediatr       Date:  2011-09-26       Impact factor: 2.125

4.  Porcine circovirus type 1 was undetected in vaccine but could be cultured in the cell substrate of Lanzhou lamb rotavirus vaccine.

Authors:  Qingchuan Yu; Yan Liu; Jialiang Du; Yueyue Liu; Lili Zhang; Tai Guo
Journal:  J Gen Virol       Date:  2017-11-22       Impact factor: 3.891

Review 5.  Matrix and backstage: cellular substrates for viral vaccines.

Authors:  Ingo Jordan; Volker Sandig
Journal:  Viruses       Date:  2014-04-11       Impact factor: 5.048

6.  Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial.

Authors:  Ignacio Salamanca de la Cueva; Barbara Pahud; Li-Min Huang; Michael Leonardi; José Garcia-Sicilia; Javier Céspedes; Arturo Abdelnour; Tsuyoshi Tamura; Haruo Kuroki; Nan-Chang Chiu; Miia Virta; Satu Kokko; Michael Horn; Falko Panzer; Jong-Hyun Kim; Lee Jin; Leentje Moerman; Christophe Debacq; Jose Parra; Ana Ugarte; Dan Bi
Journal:  J Infect Dis       Date:  2020-05-04       Impact factor: 7.759
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.